Investigating how SERBP1 affects gene regulation in glioblastoma
Official title: SERBP1 as a dual modulator of epigenetic regulation in glioblastoma
Funded at University of Texas Hlth Science Center · NIH-11139745 · Data updated 2026-11-12
This study is looking at a protein called SERBP1 to see how it affects brain cancer stem cells and makes glioblastoma more aggressive, with the hope that understanding this could lead to better treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $433,125 |
| NIH project number | 1R21NS137252-01A1 |
| Project ID | NIH-11139745 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma, particularly those with high levels of SERBP1 expression.
✕Less likely to help
Patients with other types of brain tumors or those without glioblastoma may not receive direct benefits from this research.
What this research studies
This research focuses on the role of the RNA binding protein SERBP1 in glioblastoma (GBM), a type of brain cancer. It aims to understand how SERBP1 influences the differentiation of cancer stem cells and contributes to the aggressive nature of GBM. By using advanced techniques like RNA sequencing and ATAC sequencing, the researchers will explore the epigenetic mechanisms through which SERBP1 operates, potentially revealing new pathways that could be targeted for treatment. Patients may benefit from insights gained about the molecular underpinnings of their condition, which could lead to more effective therapies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with glioblastoma.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic factors in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Penalva, Luiz Otavio — University of Texas Hlth Science Center
- Study coordinator: Penalva, Luiz Otavio
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.